PrimeVax Immuno-Oncology

📍 South San Francisco, United States🗓 Founded 2015👥 6 employees💰 Last funded 2021
Biotechnology Research🌐 primevax.com
Website LinkedIn
PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in PrimeVax Immuno-Oncology?
PrimeVax Immuno-Oncology has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did PrimeVax Immuno-Oncology last raise funding?
The most recent investment in PrimeVax Immuno-Oncology recorded on gritt.io was in 2021.
When was PrimeVax Immuno-Oncology founded?
PrimeVax Immuno-Oncology was founded in 2015.
What industry is PrimeVax Immuno-Oncology in?
PrimeVax Immuno-Oncology operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is PrimeVax Immuno-Oncology based?
PrimeVax Immuno-Oncology is headquartered in South San Francisco, United States.